Longitudinal short-term assessments of single- and multi-protein disease activity biomarkers to determine reliability and the minimum detectable change in people with clinically stable RRMS [0.03%]
单一和多蛋白疾病活性生物标志物纵向短期评估的可靠性和临床稳定复发缓解型多发性硬化症中最小检测变化测定
Shannon McCurdy,Elisa Sheng,Kian Jalaleddini et al.
Shannon McCurdy et al.
Objectives: This study aims to evaluate the ability of a multi-protein biomarker score to characterize clinical stability in relapsing-remitting multiple sclerosis (RRMS) compared to that of single-protein markers. ...
Kappa free light chain index or oligoclonal bands testing in clinical practice for multiple sclerosis diagnosis: An algorithm comparative study [0.03%]
κ型自由轻链指数或寡克隆带检测在多发性硬化症诊断中的临床应用：一种算法比较研究
Michaël Levraut,Mikael Cohen,Delphine Sterlin et al.
Michaël Levraut et al.
Background: Limited evidence exists on how to use kappa free light chains (κFLCs) and oligoclonal bands (OCBs) in diagnosing intrathecal immunoglobulin synthesis (IgS). ...
Early use of high-efficacy disease-modifying therapies reduces the risk of progression independent of relapse and MRI activity in patients with relapsing-remitting multiple sclerosis [0.03%]
早期使用高效疾病修正治疗可降低复发性多发性硬化症患者的进展风险，与复发和MRI活性无关
María F Guarnaschelli,Mariano Marrodan,Braian E Sosa et al.
María F Guarnaschelli et al.
Background: Progression independent of relapse and MRI activity (PIRMA) is a major contributor to long-term disability in relapsing-remitting multiple sclerosis (RRMS). In Latin America, limited access to high-efficacy di...
Use of semaglutide and tirzepatide among people with multiple sclerosis [0.03%]
用于多发性硬化症患者的司美格鲁肽和 tirzepatide 使用情况
Amber Salter,Alexis Novak,Samantha Lancia et al.
Amber Salter et al.
Background and objectives: Little is known about glucagon-like peptide-1 receptor agonists (GLP1RAs) use in multiple sclerosis. We described the frequency and characteristics associated with use. ...
Non-MRI biomarkers should be accepted to guide treatment escalation in MS: Yes [0.03%]
非MRI生物标志物应该被接受来指导MS的治疗升级：同意
Adrian-Minh Schumacher,Charlotte E Teunissen
Adrian-Minh Schumacher
Non-MRI biomarkers should be accepted to guide treatment escalation in MS: NO [0.03%]
无MRI生物标志的患者应被接受提升治疗力度:NO
James M Stankiewicz
James M Stankiewicz
Utility, validity, feasibility and acceptability of a clinician-administered depression, two-question screening tool for routine multiple sclerosis clinic administration [0.03%]
一种针对多发性硬化症患者的抑郁筛查工具的效用、有效性和可行性研究
Lisa Grech,Michelle Allan,David Skvarc et al.
Lisa Grech et al.
Background: Depression is prevalent among individuals with multiple sclerosis (MS) yet frequently goes undetected and untreated. Time constraints are a barrier to depression screening in MS clinics. We evaluated the clini...